

SCHERING-PLOUGH CORPORATION  
LAW DEPARTMENT  
2000 GALLOPING HILL ROAD  
K-6-1, MAIL STOP 1990  
KENILWORTH, NEW JERSEY 07033  
(908) 298-4000

RECEIVED  
CENTRAL FAX CENTER  
JUL 12 2004

## FACSIMILE TRANSMITTAL SHEET

TO:

Examiner Shengjun Wang  
USPTO

FAX NUMBER:

(703) 308-4242  
(703) 872-9306

FROM:

Ann Marie Cannoni

PHONE NUMBER:

(908) 298-5024

TOTAL NO. OF PAGES INCLUDING COVER

60

DATE

July 12, 2004

OFFICIAL

**CONFIDENTIALITY NOTE:** This sheet and/or the document(s) accompanying it contain information belonging to Schering-Plough Corporation and/or its affiliates which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named above. If you have received this fax in error, please immediately notify us by telephone. If there is a problem with this transmission please call Shawn Armstrong at (908) 298-5255.

NOTES/COMMENTS:

## PLEASE HAND DELIVER

In re Application of: **Harry R. Davis et al.**For Patent For: **Combinations of Bile Acid Sequestrant(s) and Sterol Absorption Inhibitor(s) and Treatments for Vascular Indications**


Group Art Unit: 1617 Filed: 01/25/2002

Attorney Docket No.: CV01378K US/ Serial No.: 10/057,534

Dear Examiner Wang:

Transmitted herewith are:

- > Response Transmittal PTO/SB/21 - 1 Page
- > Amendment After Final Rejections - 58 Pages
- > Fax Cover Sheet - 1 Page

  
Ann Marie Cannoni  
Registered Representative  
Registration No. 35,972

PTO/SB/21 (02-04)


Approved for use through 07/31/2006. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	10/057,534	
	Filing Date	01/25/2002	
	First Named Inventor	Harry R. Davis et al.	
	Art Unit	1617	
	Examiner Name	Shengjun Wang	
Total Number of Pages in This Submission	60	Attorney Docket Number	CV01378K

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input checked="" type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): Fax Cover Sheet - 1 Page
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Ann Marie Cannoni
Signature	
Date	07/12/2004

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Ann Marie Cannoni, Reg. No. 35,972
Signature	
Date	07/12/2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED  
CENTRAL FAX CENTER  
JUL 12 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**OFFICIAL**

In re: Patent Application of : PATENT APPLICATION  
Harry R. Davis :  
Serial No.: 10/057,534 : Group Art Unit: 1617  
Filed: January 25, 2002 : Examiner: Shengjun Wang  
For: Combinations of Bile Acid Sequestrant(s): Atty. Docket No.: CV01378K  
and Sterol Absorption Inhibitor(s) and :  
Treatments for Vascular Indications :

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT AFTER FINAL REJECTION****Introductory Comments**

This Amendment After Final Rejection is being submitted in response to the final Office Action mailed on May 12, 2004. Applicants respectfully request that these amendments to present rejected claims in better form for appeal be entered into the file record and considered under 37 C.F.R. § 1.116.

Claims 1-3, 5-28, 31-36, 70-72, 74-77, 79 and 80 are pending in the application. Claims 4, 29, 30, 37-69, 73, 78 and 81 have been withdrawn from consideration by the Examiner as being non-elected. Claim 7 has been canceled, without prejudice to filing one or more related applications directed to the canceled subject matter thereof.

Applicants have amended the claims as discussed in detail below.